Evidence map›Paper›PMID 36035359›Full record

ArticleJHEP reports : innovation in hepatology2022

Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses.

Yongzhen Liu, Debby Park, Thomas R Cafiero, Yaron Bram, Vasuretha Chandar, Anna Tseng, Hans P Gertje, Nicholas A Crossland, Lishan Su, Robert E Schwartz and 1 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Anticodon Engineered Transfer RNA (tRNAAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis.International journal of molecular sciences · 2023
    Review
  8. Translational cancer research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yongzhen LiuDepartment of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Debby ParkDepartment of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Thomas R CafieroDepartment of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Yaron BramDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Vasuretha ChandarDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Anna TsengNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Hans P GertjeNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Nicholas A CrosslandNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Lishan SuDivision of Virology, Pathogenesis and Cancer, Institute of Human Virology, Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.
Robert E SchwartzDivision of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Alexander PlossDepartment of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Princeton University · USBoston University · USCornell University · USUniversity of Maryland, Baltimore · US

Funding

Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Genetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0M
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infectionR01AI138797 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PLOSS, ALEXANDER, SU, LISHAN · 2018 to 2022
$3.9M
Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment ResponseR01AI146917 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL · 2020 to 2024
$3.5M
Mechanisms of hepatitis B virus cccDNA formationR01AI153236 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2020 to 2024
$2.8M
Optimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyteR01DK121072 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2020 to 2024
$2.6M
Vectra Polaris Quantitative Pathology Imaging SystemS10OD030269 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2021 to 2021
$402k
Ventana Discovery Ultra Research Autostainer: an Ex+ Core serviceS10OD026983 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CROSSLAND, NICHOLAS ALEXANDER · 2019 to 2019
$207k
NIAID NIH HHS R01 AI107301NIAID NIH HHS R01 AI138797NIAID NIH HHS R01 AI146917NIAID NIH HHS R01 AI153236NIAID NIH HHS R01 AI168048NIDDK NIH HHS R01 DK121072NIH HHS S10 OD026983NIH HHS S10 OD030269
6 · The paper itself

Abstract

Background & Aims: HBV exhibits wide genetic diversity with at least 9 genotypes (GTs), which differ in terms of prevalence, geographic distribution, natural history, disease progression, and treatment outcome. However, differences in HBV replicative capacity, gene expression, and infective capability across different GTs remain incompletely understood. Herein, we aimed to study these crucial aspects using newly constructed infectious clones covering the major HBV GTs. Methods: The replicative capacity of infectious clones covering HBV GTs A-E was analyzed in cell lines, primary hepatocytes and humanized mice. Host responses and histopathology induced by the different HBV GTs were characterized in hydrodynamically injected mice. Differences in treatment responses to entecavir and various HBV capsid inhibitors were also quantified across the different genetically defined GTs. Results: Patient-derived HBV infectious clones replicated robustly both Conclusions: The infectious clones described here have broad utility as genetic tools that can mechanistically dissect intergenotypic differences in antiviral immunity and pathogenesis and aid in HBV drug development and screening. Lay summary: The hepatitis B virus (HBV) is a major contributor to human morbidity and mortality. HBV can be categorized into a number of genotypes, based on their specific genetic make-up, of which 9 are well known. We isolated and cloned the genomes of 5 of these genotypes and used them to create valuable tools for future research on this clinically important virus.

Indexed as

AAV, adeno-associated virusALT, alanine aminotransferaseBCP, basic core promotercccDNA, covalently closed circular DNACHB, chronic hepatitis BCpAM, core protein allosteric modulatorsdpi, days post infectionDR, direct repeatdrug developmentEn, enhancerETV, entecavirgenotypesGT(s), genotype(s)HBVcc, cell culture-derived HBVHBV, hepatitis B virusHCC, hepatocellular carcinomaHDI, hydrodynamic injectionhepatitis Bhepatitis B virushost responsesIFN, interferonIHC, immunohistochemistryIL, interleukinMOI, multiplicity of infectionNA, nucleos(t)ide analogueNRG, NODRag1−/−IL2RγNULLpgRNA, pre-genomic RNAPHH, primiary human hepatocytereverse geneticsSVR, sustained virologic responseviral hepatitis

Identifiers

PMID36035359
PMCPMC9403497
OpenAlexW4284991881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.